5 results about "Gossypol Acetate" patented technology

Provided is the application of a compound in anti-coronavirus. The application is the application of a compound or a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a crystal form thereof in the preparation of an anti-coronavirus preparation, wherein the compound is selected from one or more of gossypol acetic acid, mecobalamin, ertapenem, chaetocidin, netilmicin sulfate, sennoside A and ellagic acid. In the application, the compound can effectively inhibit coronavirus RNA-dependent RNA polymerase (RDRP), thereby inhibiting the proliferation of coronavirus and being applied to anti-coronavirus. The inhibition effect is strong, the cost is low, and the required dose is small, and the compound can be effectively used in anti-coronavirus.

The invention relates to the technical field of microbial fermentation and feed production, in particular to a free gossypol degrading bacterium YJQ-1 and application thereof.The free gossypol degrading bacterium YJQ-1 is Wickerhamomyces anomalus, is preserved in the China Center for Type Culture Collection on March 4, 2026, has the preservation number of CCTCC M 2026367 and is separated from Sichuan Dazhou sweet distiller's yeast. The strain can tolerate 2.0 g / L of gossypol acetate, and the degradation rate of 1.0 g / L of gossypol acetate within 72 h reaches 83.75%. The microbial inoculum prepared from the strain is inoculated to cottonseed meal sieved by a 40-mesh sieve according to the inoculum size of 5%, the moisture content is adjusted to 40%, solid state fermentation is performed at 30 DEG C for 7 days, the gossypol degradation rate is 86.52%, the free gossypol is only 144 mg / Kg, and nutritional indexes such as cottonseed meal crude protein and protein digestibility are remarkably improved. The technology is low-carbon and environment-friendly, the application range of the cottonseed meal is widened, and a foundation is laid for biological manufacturing of oil processing byproduct protein resources.

The invention relates to application of gossypol in preparation of a medicine for treating chicken necrotic enteritis, and belongs to the field of medicine. In-vitro antibacterial activity tests, hemolytic activity inhibition tests, biofilm formation inhibition tests and chicken necrotic enteritis model tests prove that gossypol has a prevention and treatment effect on chicken necrotic enteritis caused by clostridium perfringens infection. The gossypol is preferably gossypol acetate, the minimum inhibitory concentration of the gossypol acetate to clostridium perfringens is 16 mu g / mL, and the minimum bactericidal concentration of the gossypol acetate to clostridium perfringens is 32 mu g / mL. It is found for the first time that gossypol can play a dual anti-infection role by inhibiting the hemolytic activity and biofilm formation of clostridium perfringens. The gossypol provided by the invention can effectively inhibit the growth of clostridium perfringens and the expression of virulence factors of the clostridium perfringens, meanwhile, the intestinal injury and growth performance of sick chickens are improved, and a new technical scheme is provided for green prevention and control of chicken necrotic enteritis.

The application discloses a combined medicine of acacetin acetate and a CDK4 / 6 inhibitor, and relates to the technical field of medicines. The medicine composition comprises a CDK6 negative regulator and a CDK4 / 6 inhibitor; the CDK6 negative regulator comprises acacetin acetate or a baicalein derivative. The application proposes a treatment scheme of the combined medicine of acacetin acetate and the CDK4 / 6 inhibitor or a treatment scheme of the combined medicine of the baicalein derivative and the CDK4 / 6 inhibitor, which exhibits excellent synergistic effect and can effectively improve the treatment effect on patients who are not sensitive to the CDK4 / 6 inhibitor.